Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers

Digestion

Volumn 60, Issue 2, 1999, Pages 132-140

  Schiedermaier, P ^a   Brensing, K A ^b   Goke B ^b   Schatzle T ^b   Sauerbruch, T ^b  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

Doppler ultrasound; Dose effect; Glucagon; Octreotide; Portal blood flow; Splanchnic blood flow

Indexed keywords

GLUCAGON; OCTREOTIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCAGON BLOOD LEVEL; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESENTERY BLOOD FLOW; NORMAL HUMAN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIAL; SPLANCHNIC BLOOD FLOW; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERIOR MESENTERIC ARTERY; VOLUNTEER;

EID: 0033055290     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007638     Document Type: Article

References (35)

1. Cooper AM, Braatvedt GD, Qamar MI, Brown H, Thomas DM, Halliwell M, Read AE, Corrall RJ: Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. Clin Sci 1991;81:169-175.
2. Chemnitz J, von-zur-Mühlen A, Schürmeyer TH: Effects of octreotide and glucagon on splanchnic hcmodynamics in healthy volunteers (abstract). Eur J Clin Pharmacol 1994;47: 96.
3. McCormick PA, Dick R, Siringo S, Wagstaff D, Chesta J, McIntyre N, Burroughs AK: Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. J Gastroenterol Hepatol 1990;2:489-492.
4. Jenkins SA, Baxter JN, Corbett WA, Shields R: Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985;72:1009-1012.
5. Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F: Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Invest 1994;72:653-659.
6. Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, Leung VK, Li MK, Li AK: Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopie ligation. Lancet 1995;346: 1666-1669.
7. Besson I, Ingrand P, Person B, Boutroux D, Hercsbach D, Bernard P, Hochain P, Larricq J, Gourlaouen A, Ribard D, Kara NM, Legoux JL, Becker MC, Di Costanzo J, Metreau JM, Silvain C, Beauchant M: Sclerotherapy with or without octreotide for acute variccal bleeding. N Engl J Med 1995;333:555-560.
8. Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, Grime JS, Love JG, Sutton R: Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997;315: 1338-1341.
9. Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, Staudacher C, Beretta L, Motta R, de Franchis R: Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopie Club. Hepatology 1995;21:1322-1327.
10. Burroughs AK: Double blind ret of 5 days octreotide versus placebo, associated with sclerotherapy for trial/failures (abstract). Hepatology 1996;24:352.
11. Zironi G, Rossi C, Siringo S, Galaverni C, Gaiani S, Piscaglia F, Bolondi L: Short-and long-term hemodynamic response to octreotide in portal hypertensive patients: A double-blind, controlled study. Liver 1996;16:225-234.
12. Wahren J, Eriksson LS: The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol Suppl 1986;119:103-108.
13. Escorsell A, Bandi JC, Francois E, Moitinho E, Andreu V, Garcia Pagan JC, Bosch J, Rodés J: Desensitation to the effectis of intravenous octreotide in cirrhotic patients with portal hypertension (abstract). Hepatology 1996;24:204.
14. Nevens F, Van Steenbergen W, Yap SH, Fevery J: Assessment of variceal pressure by continuous non-invasive endoscopic registration: A placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996;38:129-134.
15. Reikeras O, Gunnes P: Effects of high doses of insulin on systemic haemodynamics and regional blood flows in dogs. Clin Physiol 1986;6: 129-138.
16. Eriksson LS, Hagenfeldt L, Mutt V, Wahren J: Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects. Peptides 1989;10:481-484.
17. Rozsa Z, Varro V: Mechanism of 'substance P' on mesenteric blood flow: Interactions with opioid peptides. Neuropeptides 1987:10:275-290.
18. Hori N, Okanoue T, Sawa Y, Mori T, Kashima K: Effect of a somatostatin analogue (SMS 201-995) on hemodynamics and glucagon secretion in cirrhotic rats. Gastroenterol Jpn 1993;28: 276-283.
19. Benoit JN, Zimmerman B, Premen AJ, Go VL, Granger DN: Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986;251:G674-G677.
20. Kravetz D, Bosch J, Arderiu MT. Pizcueta MP, Casamitjana R, Rivera F, Rodes J: Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-G328.
21. Donckier J, Stoleru L, Selvais P, Galanti L, Van Mechelen H, Ketelslegers JM, Charlier AA: Effects of octreotide on cardiovascular hormones and haemodynamics in conscious dogs. J Endocrinol Invest 1996;19:106-113.
22. Schirra J, Sturm K, Leicht R, Arnold R, Göke B, Katschinski M: Exendin(9-39)amid is an antagonist of glucagon-like peptide-1(7-36)amid in humans. J Clin Invest 1998;101:1421-1430.
23. Siringo S, Piscaglia F, Zironi G, Gaiani S, Sofia S, Casali A, Carbone C, Serra C, Miglioli M, Corinaldesi R, Bolondi L: Splanchnic hemodynamic response to meal in cirrhotics with different risk of variceal bleeding (abstract). Gastroenterology 1996;110:1329.
24. Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, Garcia P, Escartin P: Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21:88-94.
25. Buonamico P, Sabba C, Garcia Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen JE, Lerner E, Taylor KJ, Albano O, et al: Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-Doppler study. Hepatology 1995;21:134-139.
26. Eriksson LS, Wahren J: Intravenous and subcutaneous administration of a long-acting somatostatin analogue: Effects on glucose metabolism and splanchnic haemodynamics in healthy subjects. Eur J Clin Invest 1989;19: 213-219.
27. Sung JJ, Chung SC, Lai CW, Chan FK, Leung JW, Yung MY, Kassianides C, Li AK: Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993;342:637-641.
28. Jenkins SA, Shields R, Davies M, Elias E, Thumbull AJ, Bassendine MF, James OFW, Iredale JP, Vyas SK, Arthur MJP, Kingsnorth AN, Sutton R: A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-533.
29. Silva G, Navasa M, Bosch J, Chesta J, Pilar Pizcueta M, Casamitjana R, Rivera F, Rodes J: Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990;11:668-673.
30. Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, D'Onofrio F: The vascular effects of L-arginine in humans. The role of endogenous insulin. J Clin Invest 1997;99:433-438.
31. Karalis K, Mastorakos G, Chousos G, Tolis G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93: 2000-2006.
32. Lopez-Talavera J, Merril W, Groszmann R: Tumor necrosis factor a: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-767.
33. Sieber CC, Lee FY, Groszmann RJ: Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats. Hepatology 1996;23:1218-1223.
34. Dimech J, Feniuk W, Latimer RD, Humphrey PP: Somatostatin-induced contraction of human isolated saphenous vein involves sst2 receptor-mediated activation of L-type calcium channels. J Cardiovasc Pharmacol 1995;26: 721-728.
35. Sieber CC, Mosca PG, Groszmann RJ: Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. AmJ Physiol 1992;262:G274-G277.